MANAGEMENT OF PATIENTS WITH THYROIDASSOCIATED OPHTHALMOPATHY: ROLE OF SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY Tiroid İlişkili Oftalmopatili Hastaların Yönetimi: Spektral Alan Optik Koherens Tomografinin Rolü

Yıl 2022, Cilt: 12 Sayı: 3, 69 - 77, 15.09.2022

Kenan Dagdelen Ömer Ersin Muz

Öz

ABSTRACT
Objective: To demonstrate the changes in optic nerve head (ONH), retinal nerve fiber layer (RNFL) and
macula in patients with thyroid-associated ophthalmopathy (TAO) by spectral domain optical coherence
tomography (SD-OCT).
Material and Methods: We included forty-one eyes of 41 patients with a diagnosis of TAO and forty-eight
eyes of 48 age- and sex-matched healthy subjects (control group) from June 2016 to July 2018. The ONH
parameters, RNFL and macular thicknesses in the nine macular quadrants were measured with SD-OCT.
Proptosis level was determined by Hertel exophthalmometer. Clinical activity score (CAS) according to the
European Group of Graves' Orbitopathy (EUGOGO) guidelines was determined in all patients. Student t-test
was used to compare study and control groups. A p value less than 0.05 was considered as statistically
significant.
Results: Superior, inferior, and average RNFL thicknesses were significantly lower in the TAO group compared
to the control group (p < 0.05). Optic disc area was significantly larger in the TAO group. Outer quadrant
macular thicknesses and average macular thicknesses were significantly lower in the TAO group (p < 0.05).
CAS had a weak correlation with RNFL thickness and average macular thickness.
Conclusion: Alterations in RNFL thicknesses and macular thicknesses can be detected before the development
of ocular symptoms in patients with TAO. Patients can be diagnosed at an early stage prior to the
development of functional damage. However, the low number of studies investigating this subject and the
conflicting findings of existing studies necessitate further studies.

Anahtar Kelimeler

MANAGEMENT OF PATIENTS WITH THYROIDASSOCIATED, OPHTHALMOPATHY: ROLE OF SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY, Tiroid İlişkili Oftalmopatili Hastaların Yönetimi: Spektral Alan Optik Koherens Tomografinin Rolü

Kaynakça

• 1. Şahlı E, Gündüz K. Thyroid-associated Ophthalmopathy. Turk J Ophthalmol. 2017;47(2):94-105
• 2. Bahn RS. Thyrotropin receptor expression in orbital adipose/connective tissues from patients with thyroid-associated ophthalmopathy. Thyroid. 2002;12(3):193-5.
• 3. F. Menconi, C. Marcocci, and M. Marino, “Diagnosis and `classification of Graves’ disease,” Autoimmunity Reviews. 2014;13(4-5), 398–402
• 4. Kalmann R, Mourits MP. Late recurrence of unilateral graves orbitopathy on the contralateral side. Am J Ophthalmol. 2002;133(5):727-9
• 5. Eckstein AK, Plicht M, Lax H, Neuhäuser M, Mann K, Lederbogen S, et al. Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab. 2006;91(9):3464-70.
• 6. Blum Meirovitch S, Leibovitch I, Kesler A, Varssano D, Rosenblatt A, Neudorfer M. Retina and Nerve Fiber Layer Thickness in Eyes with Thyroid-Associated Ophthalmopathy. Isr Med Assoc J. 2017;19(5):277-81.
• 7. Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, et al European Group on Graves' Orbitopathy (EUGOGO). The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy. Eur Thyroid J. 2016;5(1):9-26.
• 8. Anderson RL, Tweeten JP, Patrinely JR, Garland PE, Thiese SM. Dysthyroid optic neuropathy without extraocular muscle involvement. Ophthalmic Surg. 1989;20(8):568-74.
• 9. Mugdha K, Kaur A, Sinha N, Saxena S. Evaluation of retinal nerve fiber layer thickness profile in thyroid ophthalmopathy without optic nerve dysfunction. Int J Ophthalmol. 2016;9(11):1634-37.
• 10. Wollstein G, Ishikawa H, Wang J, Beaton SA, Schuman JS. Comparison of three optical coherence tomography scanning areas for detection of glaucomatous damage. Am J Ophthalmol. 2005;139(1):39-43.